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Abstract: Glycemic control remains the major therapeutic objective to prevent or delay the 
onset and progression of complications related to diabetes mellitus. Insulin therapy represents a 
cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. 
Nevertheless, a large portion of the population with diabetes does not meet the  internationally 
agreed glycemic targets. Moreover, insulin treatment, especially if  intensive, may be associated 
with emergency room visits and hospitalization due to hypoglycemic events. Therefore, fear of 
hypoglycemia or hypoglycemic events represents the main barriers to the attainment of glycemic 
targets. The burden associated with multiple daily injections also remains a significant obstacle 
to initiating and maintaining insulin therapy. The most attractive insulin treatment approach 
should meet the patients’ preference, rather than demanding patients to change or adapt their 
lifestyle. Insulin degludec/insulin aspart (IDegAsp) is a new combination, formulated with 
ultra-long-acting insulin degludec and rapid-acting insulin aspart, with peculiar pharmacological 
features, clinical efficacy, safety, and tolerability. IDegAsp provides similar, noninferior glyce-
mic control to a standard basal–bolus regimen in patients with type 1 diabetes mellitus, with 
additional benefits of significantly lower episodes of hypoglycemia (particularly nocturnal) and 
fewer daily insulin injections. Moreover, although treatment strategy and patients’ viewpoint are 
different in type 1 and type 2 diabetes, trial results suggest that IDegAsp may be an appropriate 
and reasonable option for initiating insulin therapy in patients with type 2 diabetes inadequately 
controlled on maximal doses of conventional oral agents. This paper will discuss the role of 
IDegAsp combination as a novel treatment option in diabetic patients.
Keywords: diabetes mellitus, insulin analogs, insulin degludec/insulin aspart, IDegAsp, 
hypoglycemia
Introduction
Diabetes mellitus (DM) has become a widespread epidemic, and the number of people 
with diabetes will more than double over the next years, due to population growth and 
aging.1 Good glycemic control remains the basis of managing diabetes and plays a key 
role in preventing or delaying the onset and progression of diabetic  complications in 
both patients with type 1 or type 2 DM. The American Diabetes Association and the 
European Association for the Study of Diabetes have released statements on glycemic 
goals, advocating the early use of insulin.2 Insulin therapy represents a cornerstone in 
the treatment of all patients with type 1 DM, and it is indicated in most patients with 
type 2 DM. Prospective randomized clinical trials have demonstrated that improved 
glycemic control is associated with sustained decreased rates of microvascular 
complications.3–6
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Recent publications continue to underline the  essential 
role of good glycemic control in reducing the risk of dia-
betes complications.7 On the other hand, whether good 
glycemic control has any impact on reducing macrovascular 
complications is still a matter of debate. When all the large, 
long-term, prospective randomized controlled clinical trials 
(such as the United Kingdom Prospective Diabetes Study 
[UKPDS], the prospective pioglitazone clinical trial in mac-
rovascular events [PROactive], the Action in Diabetes and 
Vascular Disease: Preterax and Diamicron MR Controlled 
Evaluation [ADVANCE] trial, the Veterans Affairs Diabetes 
Trial [VADT] and the Action to Control Cardiovascular 
Risk in Diabetes [ACCORD] trial) are included in a meta-
analysis, glycemic control resulted in a 17% reduction in 
events of nonfatal myocardial infarction (odds ratio [OR], 
0.83; 95% confidence interval [CI] 0.75–0.93), and a 15% 
reduction in events of coronary heart disease (OR, 0.85; 
95% CI 0.77–0.93).8
However, the effect on cardiovascular death varied 
among studies, with the evidence of statistical heterogeneity. 
 Compared with standard therapy, intensive therapy increased 
the risk of cardiovascular death in the ACCORD trial and had 
a neutral or salutary effect in the ADVANCE and the UKPDS 
trials.9 Despite better microvascular outcomes, intensive 
insulin therapy has been associated with a high rate of severe 
hypoglycemia.3,10
Similarly, the rates of major hypoglycemic episodes 
per year were higher in insulin-treated type 2 diabetes as 
compared to conventional treatments: 0.7% with conven-
tional treatment; 1.0% with chlorpropamide; 1.4% with 
glibenclamide; and 1.8% with insulin.4 The higher risk 
of hypoglycemia with intensive treatment has been con-
firmed also in the major clinical trials (VADT, ADVANCE, 
ACCORD, and PROactive).11 Moreover, results of the post-
hoc analyses of both the ACCORD and VADT trials have 
shown a strong association between severe hypoglycemia and 
cardiovascular mortality.12 In a very recent large prospective 
cohort of type 2 DM, severe hypoglycemia has been also 
 associated with high rates of death.13 Moreover, hypoglycemia 
has been related to recurrent morbidity, increased risk of 
emergency room visits, and hospitalization.14
New opportunities in clinical  
management of diabetes
Fear of hypoglycemia and hypoglycemia events has a large 
impact on patients’ lives and quality-of-life, and continues 
to be a major problem for diabetic people.15–18 The main 
obstacles to optimizing insulin therapy also include the 
burden  associated with multiple daily injections.19 To over-
come these barriers, a simpler insulin regimen with fewer 
daily injections could offer a greater degree of flexibility in 
dosing time, thus improving treatment adherence. The goal 
for insulin therapy is to mimic the physiological pattern of 
insulin secretion seen in nondiabetic patients, and the suc-
cess of insulin therapy ultimately depends on how closely a 
given regimen can mimic the normal physiology.20,21 In this 
perspective, the introduction of the so-called designer insu-
lins – the insulin analogs – has offered new opportunities in 
the clinical management of diabetes.22,23
Insulin analogs (the short-acting insulin analogs: lispro, 
aspart, and glulisine and the long-acting insulin analogs: 
detemir and glargine) have been shown in many instances 
to be associated with reduced risks of hypoglycemia, lower 
levels of postprandial glucose excursions, better patient 
adherence, greater quality of life, and higher satisfaction 
with treatment in both type 1 and type 2 diabetic patients, 
as compared to traditional insulins.24–29
However, in terms of pharmacokinetics and pharmaco-
dynamics, currently available insulin analogs still have some 
limitations, failing to reproducibly provide insulin cover-
age over a full 24 hours and to do so from day to day.30,31 
 Therefore, improvements are desirable, particularly in the 
area of long-acting insulin analogs, where effective once-
daily  clinical use might not be possible in all patients and may 
require patients to administer insulin at a specific time of day, 
which may not always be convenient or remembered.30
Indeed, the first generation of basal analogs like glargine 
(IGlar) and detemir (IDet) has certain shortcomings that do 
not allow them to be termed ideal basal insulins. IGlar is said 
to be peakless, but it may be associated with interindividual 
variability. Many patients exhibit peaks in action, especially 
at higher doses, while IDet, which is a peakless, stable insulin, 
may need to be injected twice daily in type 1 diabetes and 
when given in smaller doses.32
Insulin degludec (IDeg) is a neutral ultra-long-acting new 
generation basal insulin analog that was developed by Novo 
Nordisk (Bagsvaerd, Denmark) and recently approved in the 
European Union for use as basal insulin therapy in patients 
with type 1 and type 2 DM.33 IDeg has been designed to have 
a longer half-life and lower pharmacodynamic variability 
than currently available basal insulin products.34–38 The effi-
cacy and safety of IDeg in the treatment of diabetic patients 
have been evaluated in type 1 and 2 diabetes (Table 1). 
 Pharmacokinetic and pharmacodynamics data demonstrated 
that its mechanism of protraction results in an ultralong dura-
tion of action with a flat steady-state plasma profile. Clinical 
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Table 1 Summary of main studies using iDeg in patients with type 1 and type 2 DM
Authors Study design Comparators Type of patients
Birkeland Ki et al40 
Diabetes Care, 2011
16-week, randomized, controlled,  
open-label, three-arm, parallel group trial
iDeg (600 micromol/L); iDeg  
(900 micromol/L) versus iGlar
Type 1 DM
Heller S et al41 
Lancet, 2012
Open-label, treat-to-target, noninferiority  
trial
iDeg versus iGlar Type 1 DM
Heise T et al35 
Diabetes Obes Metab,  
2012
Randomized, single-center, parallel-group,  
double-blind trial
iDeg versus iGlar Type 1 DM
Mathieu C et al42 
J Clin Endocrinol  
Metab, 2013
26 + 26-week, randomized, controlled,  
open-label, multinational, para llel-design,  
treat-to-target, noninferiority trial
iDeg (once daily, varying injection  
timing day) versus iGlar
Type 1 DM
Bode Bw et al43 
Diabet Med, 2013
Open-label trial (1-year main trial + 1-year  
extension trial)
iDeg versus iGlar Type 1 DM
Koehler G et al44 
Diabetologia, 2014
Double-blind, randomized, two-period,  
crossover trial
iDeg versus iGlar Type 1 DM
Korsatko S et al45 
Drugs Aging, 2014
Single-center, randomized, multiple-dose,  
double-blind, two-period, crossover trial
iDeg (pharmacokinetics/ 
pharmacodynamics)
Type 1 DM (including elderly  
patients)
Biester T et al46 
Pediatr Diabetes, 2014
Single center, randomized, single dose,  
double-blind two-period, crossover trial
iDeg versus iGlar Type 1 DM (children,  
adolescents, and adults)
Davies MJ et al47 
Diabetes Obes Metab,  
2014
Multinational, 26-week, controlled,  
open-label, parallel group randomized trial
iDeg versus iDet Type 1 DM
Zinman B et al48 
Lancet, 2011
16-week, randomized, open-label, parallel  
group, Phase ii trial
iDeg versus iGlar Type 2 DM
Garber AJ et al49 
Lancet, 2012
52-week, Phase iii, open-label, treat-to- 
target, noninferiority trial
iDeg versus iGlar Type 2 DM
Heise T et al50 
Diabetes Obes Metab,  
2012
Randomized, single center, double-blind,  
two-period, incomplete block crossover,  
multiple dose trial
iDeg 100 U/mL 
(0.4 U/kg; 0.6 U/kg, 0.8 U/kg) 
iDeg 200 U/mL 
(0.6 U/Kg) (pharmacokinetics)
Type 2 DM
Zinman B et al51 
Diabetes Care, 2012
52-week, randomized, controlled, 1 year,  
parallel group, open-label, multinational,  
treat-to-target, noninferiority trial
iDeg versus iGlar Type 2 DM
Meneghini L et al52 
Diabetes Care, 2013
Phase iii, 26-week, randomized, controlled,  
open-label, three-arm, parallel group trial
Once-daily IDeg, in a prespecified  
dosing schedule; once-daily iDeg, 
at the main evening meal; once- 
daily iGlar, at the same time  
each day
Type 2 DM
Philis-Tsimikas A et al53  
Diabetes Obes Metab,  
2013
26-week, randomized, open-label,  
multicenter, multinational, controlled trial
iDeg versus sitagliptin Type 2 DM
Gough SC et al54 
Diabetes Care, 2013
26-week, open-label, treat-to-target trial iDeg versus iGlar Type 2 DM
Philis-Tsimikas A et al55 
Adv Ther, 2013
26-week, multinational, Phase iiib, multicenter,  
two-armed, parallel group, open-label,  
randomized, treat-to-target trial
iDeg simple algorithm versus  
iDeg stepwise algorithm
Type 2 DM
Rodbard Hw et al56 
Diabet Med, 2013
Randomized, controlled, parallel group,  
open-label, multinational, treat-to-target,  
noninferiority trial
iDeg versus iGlar Type 2 DM
Zinman B et al57 
Lancet Diabetes  
Endocrinol, 2013
Two Phase iii, 26-week, randomized,  
open-label, treat-to-target, noninferiority  
trials
iDeg injected three times a week  
versus iGlar once daily
Type 2 DM
Kiss i et al58  
Clin Pharmacokinet,  
2014
Single center, single dose, open-label,  
parallel group trial
iDeg (pharmacokinetics) Patients with normal or  
impaired renal function  
(11/30 with Type 2 DM)
Kupčová V et al59 
Clin Drug Investig, 2014
Single center, single dose, open-label,  
parallel group trial
iDeg (pharmacokinetics) Patients with hepatic impairment 
(Child-Pugh grade A, B, or C) 
(3/24 with Type 2 DM)
(Continued)
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studies have shown that these characteristics may translate 
into the achievement of glycemic control with a lower risk 
of hypoglycemia, especially at night.39
A summary of the main studies using IDeg in patients 
with type 1 and type 2 DM is reported in Table 1.
Another unique pharmacological property of IDeg is that 
it can be coformulated with insulin aspart (IAsp), resulting, 
for the first time, in a soluble preparation comprising two 
different insulin analogs: 70% of basal analog IDeg and 
30% short-acting analog IAsp (IDegAsp).64 By providing 
both basal and rapid-acting insulin analogs in one injection, 
IDegAsp marks an important innovation in insulin therapy 
and could represent a novel area for therapeutic intervention 
in diabetes.
IDeg/IAsp: notes on chemistry,  
pharmacokinetics, and  
pharmacodynamics
IDeg is a long-acting basal insulin modified such that the amino 
acid residue threonine in position B30 (ThrB30) of human 
insulin has been omitted and the ε-amino group of lysine in 
position B29 (LysB29) has been coupled to  hexadecanedioic 
acid via a spacer of glutamic acid. The structural formula is 
LysB29Nε-hexadecanoyl-γ-L-Glu desB30 human insulin with 
a molecular formula of C
274
H
411
N
65
O
81
S
6
, giving a theoretical 
average molecular weight of 6,104.1 Da (Table 2).34,37
This structure allows IDeg to form soluble and stable 
multihexamers, resulting in a depot in the subcutaneous tissue 
after the injection. The gradual separation of IDeg monomers 
from the multihexamers results in a slow and continuous 
delivery of IDeg from the subcutaneous injection site into 
the circulation, leading to flat and stable pharmacokinetic 
and pharmacodynamic profiles. The mean terminal half-life 
of insulin degludec exceeds 25 hours in patients with either 
type 1 or type 2 diabetes, with a duration of action exceeding 
42 hours in most patients.34–38
IAsp is a modified analog of human insulin where 
the amino acid proline has been replaced with aspartic 
acid at position 28. The molecular formula of IAsp is 
C
256
H
381
N
65
O
79
S
6
, and it has a molecular mass of 5,825.8 Da 
(Table 2).65 With a single amino acid change, the strength 
of binding between the monomers has been made weak; 
therefore, IAsp immediately dissociates into small, single 
monomers that are rapidly absorbed into the blood circula-
tion.66–68 The pharmacokinetic profile for IAsp has been 
well-established,68 and its use across the spectrum of diabetic 
Table 1 (Continued)
Authors Study design Comparators Type of patients
Mathieu C et al60 
Diabetes Obes Metab,  
2014
Multinational, Phase iiib, open-label,  
randomized, treat-to-target trial (52-week  
main trial BeGiN ONCe-Long + 52-week  
extension)
iDeg + liraglutide versus iDeg +  
iAsp
Type 2 DM
Rodbard Hw et al61 
Diabetes Obes Metab,  
2014
52 week open-label, treat-to-target trial iDeg versus iGlar Type 2 DM
Hompesch M et al62  
Clin Ther, 2014
Randomized, single center, double-blind, two 
period crossover trial
iDeg versus iDet Type 2 DM (African American, 
Hispanic/Latino, white)
Bode Bw et al63  
Endocr Pract, 2014
22-week, treat-to-target trial iDeg (200 U/mL) versus iDeg  
(100 U/mL)
Type 2 DM
Abbreviations: iDeg, insulin degludec; iGlar, insulin glargine; iDet, insulin detemir; type 1 DM, type 1 diabetes mellitus; type 2 DM, type 2 diabetes mellitus; iAsp, insulin aspart.
Table 2 Chemical structure and pharmacokinetic/pharmacodynamic profiles of IAsp, IGlar, IDet, and IDeg
IAsp IGlar IDet IDeg
Molecular formula C256H381N65O79S6 C267H404N72O78S6 C267H402O76N64S6 C274H411N65O81S6
Molecular weight 5,825.8 Da 6,063.0 Da 5,916.9 Da 6,103.97 Da
Formulation properties Rapid-acting analog Formation of microprecipitates, 
or stabilized aggregates; slow  
dissolution of free hexamers
Dihexamerization and  
albumin binding
Multihexamer  
formation
Onset 15 minutes 30–60 minutes 30–60 minutes 30–90 minutes
Peak 1–3 hours Relatively flat Relatively flat Flat
Duration 3–5 hours 24 hours Up to 24 hours .24 hours
Dosing Premeal Same time every day Same time every day (once- 
daily or twice-daily)
Any time of day
Abbreviations: iAsp, insulin aspart; iGlar, insulin glargine; iDet, insulin detemir; iDeg, insulin degludec; Da, dalton.
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patients has been recently reviewed.69,70 Strong  evidence has 
suggested that IAsp is suitable in different settings, such 
as emergency departments and intensive/ nonintensive care 
units, as well as in patients aged $65 years.70
A very novel and peculiar feature of IDeg, which is not 
shared by IGlar or IDet, is the possibility of being combined 
with rapid-acting IAsp.71 IGlar has been formulated with an 
amino acid substitution at position A21 (asparagine replaced 
by glycine) and two arginines at the C-terminus of the B-chain 
(B31 and B32). These changes shift the isoelectric point from 
5.4–6.7, which make the agent most soluble at a slightly 
acidic pH (pH 4) and less soluble under neutral conditions.72 
Conversely, rapid-acting insulin analogs are prepared in 
neutral formulations, becoming unstable at a slightly acidic 
pH.72 IDet, which has been modified from the human insulin 
structure through the addition of a C14 fatty acid side chain at 
position B29, is soluble in a neutral pH formulation,72 but its 
self-associated structures are less stable than the dihexamers 
of IDeg and could form, when mixed in the same formulation 
as a rapid-acting analogs, hybrid hexamers with unpredict-
able pharmacodynamics and  pharmacokinetics.34 Therefore, 
currently existing basal  insulin analogs (IGlar and IDet) are 
not available as combination formulations with fast-acting 
insulin analogs.34
Insulin degludec/insulin aspart (IDegAsp) is the first 
soluble combination of two different insulin analogs (70% 
IDeg, as basal insulin; 30% IAsp, as prandial insulin), provid-
ing basal insulin coverage and a prandial insulin bolus in a 
single injection.34 The molecular structure of IDeg allows it to 
be coformulated with IAsp in the presence of zinc and phenol, 
without the risk of hybrid hexamers formation,34 giving rise 
to an absorption profile of IDegAsp that resembles that of 
IDeg and IAsp when injected separately. In solution, the two 
insulin components exist in soluble and stable forms – IDeg as 
dihexamers and IAsp as hexamers, respectively.34,73  IDegAsp 
is able to provide a pharmacokinetic/pharmacodynamic 
 profile with a clear distinction between the effects of the 
basal (IDeg) and rapid (IAsp) components.38
Table 2 summarizes the chemical structures and 
 pharmacokinetic/pharmacodynamic profiles of IDeg, IGlar, 
IDet, and IAsp.
IDegAsp: overview of clinical  
pharmacology trials
Type 1 diabetes
The efficacy and tolerability of IDegAsp, the new insulin 
coformulation, has been evaluated in a randomized, open-
label, multicenter, 26-week, Phase III, treat-to-target trial that 
included patients (n=548) affected by type 1 diabetes for at 
least 12 months (glycated hemoglobin [HbA
1c
] 7.0%–10.0%, 
inclusive), randomized 2:1 to IDegAsp or IDet.20
In the first group of treatment, IDegAsp was given once-
daily plus mealtime IAsp for remaining meals. In the second 
group, IDet was administered in the evening and IAsp at 
all meals with a second dose of IDet added at breakfast in 
the case of inadequate glycemic control after 8 weeks. The 
IDegAsp and IDet doses were adjusted to a prebreakfast 
plasma glucose (PG) target of 4–5 mmol/L (72–90 mg/dL); 
whereas, morning doses of IDet were titrated based on the 
mean predinner PG levels, again aiming for 4–5 mmol/L. 
Changes were made on the basis of mean self-measured PG 
value from the preceding 3 days.
The primary endpoint was the change from baseline in 
HbA
1c
 after 26 weeks of treatment. Secondary endpoints 
included, among others, the percentage of patients  reaching 
HbA
1c
 ,7.0% and the change from baseline in fasting 
PG (FPG). Safety assessments comprised adverse events, 
 hypoglycemic events, insulin doses (total insulin dose and 
basal and bolus doses), body weight, laboratory tests, and 
vital signs. After 26 weeks of treatment, HbA
1c
 decreased 
over 26 weeks in both treatment strategy groups to 7.6%. 
The mean change from baseline to week 26 was –0.75% with 
IDegAsp and –0.70% with IDet. The estimated treatment 
difference (ETD) of IDegAsp versus IDet was –0.05% (95% 
CI –0.18 to 0.08), confirming the noninferiority of IDegAsp 
relative to IDet. 
Moreover, there was no significant difference in the 
 proportion of patients achieving the HbA
1c
 target of ,7.0% 
at week 26 (24.6% with IDegAsp and 20.3% with IDet; 
P=not significant [NS]). The observed mean FPG was 
8.7 mmol/L (157 mg/dL) for IDegAsp and 8.6 mmol/L 
(155 mg/dL) for IDet. The ETD of IDegAsp versus IDet 
was 0.23 (−0.46 to 0.91) mmol/L, NS; ∼4.1 (−8.3 to 16.4) 
mg/dL. At the end of the study, the total insulin dose was 13% 
lower in the  IDegAsp group (69 units [0.86 units/kg]; basal, 
29 units [0.37 units/kg]; bolus, 39 units [0.49 units/kg]) than 
in the IDet group (79 units [1.00 units/kg]; basal, 36 units 
[0.46 units/kg]; bolus, 43 units [0.54 units/kg]). The ETD 
was 0.87 units ([0.82–0.92]; P,0.0001), while the bolus 
insulin dose was not significantly different between  treatment 
groups. 
In addition, although the observed rates of overall con-
firmed hypoglycemia were not different between the groups, 
the rate of nocturnal confirmed hypoglycemia was sig-
nificantly lower in the IDegAsp group as compared with the 
IDet-treated group, corresponding to a 37% lower rate, with 
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3.71 versus 5.72 episodes/patient year (rate ratio [RR], 0.63; 
95% CI [0.49–0.81]; P,0.0003). At week 26, the observed 
mean weight gain was 1 kg . with IDegAsp (2.3 kg) than 
with IDet (1.3 kg). The ETD of IDegAsp versus IDet was 
1.04 (0.38–1.69); P,0.0021. 
No differences were observed in the other secondary 
endpoints, such as laboratory measurements, physical 
examination, vital signs, electrocardiograms, or fundoscopy. 
Overall rates of treatment emergent adverse events were 
similar between the two treatment arms. As the health-related 
quality of life is a significant part of diabetes management, 
Hirsch et al20 have taken into account the impact of IDegAsp 
on this area of care. At the end of the trial, there were no sig-
nificant differences between the treatment groups in all scores 
and domains evaluated; thus, the IDegAsp was well-tolerated 
without negative impacts on the quality of life.
In summary, the IDegAsp effectively improved glycemic 
control, being noninferior to IDet in basal–bolus therapy in 
patients with type 1 diabetes, while the total insulin dose 
and the nocturnal confirmed hypoglycemia were all lower as 
compared to IDet + IAsp. Therefore, although the superiority 
of the new insulin combination is not supported, these data 
suggest that IDegAsp may provide another opportunity – 
particularly for those with a limitation in handling classic 
multiple-dose insulin therapy with the advantage of reduced 
risk of nocturnal hypoglycemia.
Type 2 diabetes
The efficacy of IDegAsp in insulin-naïve patients with type 
2 diabetes has been evaluated in two randomized, open-label, 
multicenter, Phase II trials, in which the new formulation 
IDegAsp has been compared with two other different insulin 
analogs – IGlar or biphasic IAsp.74,75 The first 16-week, 
open-label, treat-to-target trial has compared IDegAsp with 
IGlar in diabetic patients inadequately controlled with oral 
antidiabetic drugs.74 Subjects were randomized to once-
daily IDegAsp, in two different formulations (IDeg 70% 
and IAsp 30% or IDeg 55% and IAsp 45%) or IGlar – all in 
combination with metformin. However, for the purpose of 
this review, only the first one will be considered. In the study 
by Heise,74 insulin was given before dinner and individually 
titrated based on a target fasting plasma glucose (FPG) of 
4.0–6.0 mmol/L.
The primary endpoint was change in HbA
1c
 (%) after 
16 weeks of treatment. Over the course of the 16-week 
trial, mean HbA
1c
 decreased in all groups to comparable 
levels (IDegAsp, 7.0%; IGlar, 7.1%). A similar proportion 
of patients reached end-of-trial HbA
1c
 targets of ,7.0%, 
without confirmed hypoglycemia in the last 4 weeks of 
treatment (IDegAsp, 51%; IGlar, 50%). The mean increase 
in 2-hour postdinner was significantly lower with IDegAsp 
(0.13 mmol/L) as compared with IGlar (1.63 mmol/L); 
whereas, mean FPG was similar (IDegAsp, 6.8 mmol/L; 
IGlar, 7.0 mmol/L). Hypoglycemia rates were low for 
both IDegAsp and IGlar (1.2 and 0.7 events/patient year, 
respectively), and nocturnal confirmed hypoglycemic events 
occurred rarely and in the same way (IDegAsp, one event; 
IGlar, three events). At end-of-trial, the mean daily insulin 
doses were ∼20% lower for IDegAsp than IGlar (0.38±0.16 
and 0.45±0.20 units/kg, respectively). In conclusion, in this 
trial, once-daily IDegAsp was safe and provided similar 
overall glycemic control to IGlar, with lower doses of insulin 
and better control of postdinner glucose, without incurring a 
higher risk for nocturnal hypoglycemia.
The authors also conducted a secondary analysis in a 
subset of type 2 diabetic patients that has been recently 
published.76 A total of 112 type 2 diabetic patients, treated 
with metformin, underwent continuous interstitial glucose 
(IG) monitoring for 72 hours, after 16 weeks of treatment 
with IDegAsp or IGlar, given before the evening meal.76 
The IDegAsp treatment was associated with flatter and more 
stable nightly glucose profiles than those observed with 
IGlar. The observed mean fluctuation in nocturnal IG was 
1.13 versus 1.30 mmol/L with IDegAsp and IGlar.76 Noctur-
nal rates of high IG episodes were 48% lower with IDegAsp, 
while the rates of nocturnal low interstitial glucose levels 
did not differ between groups.76 As expected, IDegAsp was 
 associated with reduced postdinner IG excursions (IDegAsp/
IGlar, −1.42 mmol/L [−2.15, −0.70] mmol/L).
In summary, the administration at dinner of IDegAsp in 
type 2 diabetic patients can provide better postdinner PG 
levels, less nocturnal PG variability at a rate of nocturnal 
hypoglycemia that is low and comparable to that observed 
with IGlar.
In the second Phase II, open-label, three-arm, parallel 
group, randomized, controlled, 16-week, treat-to-target trial, 
the efficacy and safety of IDegAsp have been compared 
with biphasic IAsp 30 (BIAsp 30, 30% v/v soluble IAsp 
and 70% v/v protamine-crystallized IAsp), both given 
twice daily in combination with metformin, in insulin-naïve 
subjects with type 2 diabetes inadequately controlled with 
oral antidiabetic drugs.75 Insulin-naïve subjects have been 
randomized to twice-daily IDegAsp, alternative IDegAsp 
formulation (containing 45% IAsp) or BIAsp 30 – all in 
combination with metformin. As for the study by Heise,74 
the results for IDegAsp 55:45 are not discussed here. The 
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starting insulin dose was six units before breakfast and  dinner 
(main  evening meal). The breakfast dose was adjusted on 
the basis of  predinner self-measured PG values, while the 
dinner dose was adjusted according to the prebreakfast self-
measured PG values, aiming at a PG level of 4.0–6.0 mmol/L. 
The primary endpoint was change in HbA
1c
 after 16 weeks 
of treatment compared with baseline.
After 16 weeks of treatment, mean reductions in HbA
1c
 
were comparable for both treatment groups (6.7% for both 
IDegAsp and BIAsp 30). With IDegAsp, a significantly 
higher proportion of patients (67%) achieved HbA
1c
 7.0% in 
the absence of confirmed hypoglycemia in the last 4 weeks of 
treatment, as compared with BIAsp 30 (40%). Mean fasting PG 
values were significantly lower for IDegAsp versus BIAsp 30 
(treatment difference, −0.99 mmol/L [95% CI −1.68; −0.29]). 
Moreover, IDegAsp was associated with a significantly 
lower rate of confirmed hypoglycemia (58%) versus BIAsp 
30 (RR: 0.42, 95% CI: [0.23; 0.75]). Finally, IDegAsp had 
numerically lower rates of nocturnal confirmed hypoglycemia 
as compared to BIAsp 30 (0.4 versus 1.1 episodes/ 
patient year; RR: 0.33, 95% CI: [0.09; 1.14]). These results 
show that IDegAsp provided comparable overall glycemic 
control to BIAsp 30, but with a significantly lower rate of 
hypoglycemia.
More recently, the efficacy and safety of IDegAsp have 
been investigated in a (confirmatory) Phase III, 26-week, 
open-label, treat-to-target trial, which recruited 296  Japanese 
insulin-naïve type 2 diabetic subjects, inadequately controlled 
with oral antidiabetic drugs alone, randomized to once-daily 
injections of IDegAsp or IGlar.77 After 26 weeks, mean HbA
1c
 
was 7% with IDegAsp and 7.3% with IGlar. The estimated 
treatment difference (ETD) for IDegAsp/IGlar was −0.28% 
points; 95% CI [−0.46; −0.10]; P,0.01. This demonstrates 
the superiority of IDegAsp as compared to IGlar in terms of 
lowering HbA
1c
.77 At end-of-trial, the mean FPG was similar 
between the two treatments, not significantly different for 
IDegAsp and IGlar (5.7 versus 5.6 mmol/L). The ETD was 
IDegAsp/IGlar, 0.15 mmol/L [−0.29; 0.60] (95% CI).77
Noteworthy, the estimated rate of confirmed hypoglycemia 
was lower by 27% with IDegAsp than it was with IGlar. 
 Similarly, the estimated rate of nocturnal confirmed hypo-
glycemia was lower in IDegAsp-treated patients by 25% – 
although the difference was not statistically significant in both 
cases. Regarding other safety results, the mean daily insulin 
doses, increase in body weight, and adverse event profiles 
were similar between the groups.77 Overall, these results 
show, in a specific ethnic group, the superiority of IDegAsp 
versus IGlar in providing good glycemic control. Therefore, 
IDegAsp, in special settings, may represent a real alternative 
treatment option and not just another insulin.
The main studies using IDeg/IAsp in patients with type 1 
and type 2 DM are summarized in Table 3.
Conclusion
Good glycemic control remains the basis of managing DM 
and treating to target is the crucial goal to prevent and/or 
delay the onset of diabetic complications in patients with type 
1 or type 2 diabetes.2 Determinants for achieving glycemic 
control are complex, and the reasons for poor  glycemic con-
trol in diabetes are multifaceted. Intensive  glucose therapy is 
Table 3 Summary of main studies using iDeg/iAsp in patients with type 1 and type 2 DM
Authors Study design Comparators HbA1c change % Hypo (PYE) Nocturnal  
hypo (PYE)
Type of DM 
(number of 
patients)
Hirsch iB et al20 
Diabetes Care,  
2012
26-week, multinational,  
multicenter, open-label, two- 
arm, parallel, randomized,  
treat-to-target trial
iDegAsp versus  
iDet
iDegAsp, −0.75;  
iDet, −0.70
iDegAsp, 39.17;  
iDet, 44.34
iDegAsp, 3.71;  
iDet, 5.72;  
(P,0.05)
T1DM  
(n=548)
Heise T et al74 
Diabetes Care,  
2011
Phase ii, open-label,  
randomized, controlled,  
16-week trial
iDegAsp versus  
iGlar
iDegAsp, −1.3;  
iGlar, −1.3
iDegAsp, 1.2;  
iGlar, 0.7
iDegAsp, 1;  
iGlar, 3
T2DM  
(n=119)
Niskanen L et al75 
Eur J Endocrinol,  
2012
Phase ii, open-label, three-arm,  
parallel-group, randomized,  
controlled, 16-week trial
iDegAsp versus  
BiAsp 30
iDegAsp, −1.8;  
BiAsp, −1.8
iDegAsp, 2.9;  
BiAsp 30, 7.3
iDegAsp, 0.4;  
BiAsp 30, 1.1
T2DM  
(n=122)
Onishi Y et al77 
Diabetes Obes  
Metab, 2013
Phase iii, 26-week, open-label,  
randomized, stratified, parallel- 
group, multicenter, treat-to- 
target trial
iDegAsp versus  
iglar
iDegAsp, −1.4;  
iGlar, −1.2;  
(P,0.01)
iDegAsp, 1.91;  
iGlar, 2.71
iDegAsp, 0.39;  
iGlar, 0.53
T2DM  
(n=296)
Abbreviations: iDegAsp, insulin degludec/insulin aspart; iDet, insulin detemir; DM, diabetes mellitus; iGlar, insulin glargine; BiAsp 30, biphasic insulin aspart 30; hypo, 
hypoglycemia; PYe, episodes per patient/years of exposure; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; HbA1c, glycated hemoglobin.
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 associated with a higher risk of hypoglycemia that, in turn, 
has been related to recurrent  (cardiovascular) morbidity and 
an increased risk of emergency room visits and hospitaliza-
tion. A history of hypoglycemia and the fear of further epi-
sodes, particularly at night, continue to be the main barriers 
to optimizing insulin therapy. The burden of multiple daily 
insulin injections also emerges as a key obstacle to intensify-
ing therapy and/or adhering to it.15–19 Therefore, overcoming 
these barriers assumes greater priority in the treatment of 
diabetes. Although the introduction of the insulin analogs has 
offered new opportunities22,23 in terms of pharmacokinetics 
and pharmacodynamics, currently available insulin analogs 
still have some limitations.30,31
The new combination IDeg/IAsp (IDegAsp), formulated 
with ultra-long-acting IDeg and rapid-acting IAsp, with no 
molecular interactions between the two analogs, provides – in 
a single injection – specific meal coverage with full 24-hour 
basal coverage. Results from the clinical trials show that 
IDegAsp could be a promising treatment option in both 
type 1 and type 2 DM.
In type 1 diabetes, IDegAsp has shown to provide similar, 
noninferior glycemic control to a standard basal bolus regimen, 
with additional benefits of significantly lower episodes of 
hypoglycemia (particularly nocturnal) and fewer daily insulin 
injections. The complexity of some insulin regimens with 
multiple daily injections can induce some patients to regularly 
omit insulin. Conversely, a more flexible regime provided by 
IDegAsp can improve satisfaction with insulin regimen and 
the reliability of insulin use. However, a  possible limit of 
IDegAsp is the difficulty to make day-to-day dose adjustment; 
so, type 1 patients could not be the target group for IDegAsp. 
Nevertheless, for special patients, with physical or intellectual 
limitations, who would not consider self-adjusting their insulin 
doses, the use of IDegAsp may be quite convenient.
Although various viewpoints exist regarding whether 
insulin treatment should be started in type 2 diabetes and 
a variety of strategies for initiating and titrating insulin 
therapy are currently used, insulin therapy is strongly recom-
mended in type 2 diabetic patients inadequately controlled 
on  maximal doses of conventional oral agents.2
Results of clinical trials concerning the use of IDegAsp 
show that the new formulation may be an appropriate and 
reasonable option for initiating insulin therapy in type 2 
 diabetes. Indeed, in type 2 diabetic patients, IDegAsp pro-
vides comparable overall glycemic control to IGlar or BIAsp 
30, with similar low rates of hypoglycemia, as compared with 
IGlar, while the difference becomes significant with respect to 
BIAsp 30. An additional advantage of IDegAsp is the ability 
to target postprandial glucose (PPG). In this regard, several 
collections of direct and indirect evidence suggest that PPG 
is independently related to cardiovascular disease and sup-
port the idea that PPG should be assessed and that glucose 
excursions with meals should be controlled.78
Therefore, the effectiveness of IDegAsp in controlling PPG 
would be clinically relevant and should be considered also in 
the perspective to delay progression to a full basal–bolus insu-
lin replacement therapy. Based on the results of meta-analyses, 
the European Union licensed the IDeg and IDeg/IAsp combi-
nation, without any concern about cardiovascular safety.
In conclusion, IDegAsp may be a reasonable treatment 
choice in the wide range of treatment options (especially 
for type 2 diabetes). However, definitive conclusions on the 
real innovation and clinical impact of IDegAsp have to be 
 withheld, due to the fact that available data are still limited 
and trials have an open-label design and are of relatively short 
duration. Moreover, the assessment of cost-effectiveness will 
require more detailed analysis. Therefore, more information 
has to be gathered to allow critical analysis of true placement 
of IDegAsp in the treatment algorithm of diabetes.
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